Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

A Partial E3 Deletion in Replication-Defective Adenoviral Vectors Allows for Stable Expression of Potentially Toxic Transgene Products.

Haut LH, Gill AL, Kurupati RK, Bian A, Li Y, Giles-Davis W, Xiang Z, Zhou XY, Ertl HC.

Hum Gene Ther Methods. 2016 Oct;27(5):187-196. doi: 10.1089/hgtb.2016.044. Epub 2016 Sep 7.

2.

Analysis of T cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen.

Herath S, Le Heron A, Colloca S, Bergin P, Patterson S, Weber J, Tatoud R, Dickson G.

Vaccine. 2015 Dec 16;33(51):7283-7289. doi: 10.1016/j.vaccine.2015.10.111. Epub 2015 Nov 5.

3.

Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.

Lorin C, Vanloubbeeck Y, Baudart S, Ska M, Bayat B, Brauers G, Clarinval G, Donner MN, Marchand M, Koutsoukos M, Mettens P, Cohen J, Voss G.

PLoS One. 2015 Apr 9;10(4):e0122835. doi: 10.1371/journal.pone.0122835. eCollection 2015.

4.

Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity.

Teigler JE, Kagan JC, Barouch DH.

J Virol. 2014 Sep;88(18):10354-63. doi: 10.1128/JVI.00936-14. Epub 2014 Jul 2.

5.

Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens from two separate expression cassettes.

Small JC, Kurupati RK, Zhou X, Bian A, Chi E, Li Y, Xiang Z, Ertl HC.

Hum Gene Ther. 2014 Apr;25(4):328-38. doi: 10.1089/hum.2013.216. Epub 2014 Mar 25.

6.

Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.

Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, Ward BM, Bailer RT, Gottardo R, Gu W, Ferrari G, Alam SM, Denny TN, Montefiori DC, Tomaras GD, Korber BT, Nason MC, Seder RA, Koup RA, Letvin NL, Rao SS, Nabel GJ, Mascola JR.

Nature. 2014 Jan 23;505(7484):502-8. doi: 10.1038/nature12893. Epub 2013 Dec 18.

7.

Vaccines within vaccines: the use of adenovirus types 4 and 7 as influenza vaccine vectors.

Weaver EA.

Hum Vaccin Immunother. 2014;10(3):544-56. Epub 2013 Nov 26.

8.

Nonreplicating vectors in HIV vaccines.

Johnson JA, Barouch DH, Baden LR.

Curr Opin HIV AIDS. 2013 Sep;8(5):412-20. doi: 10.1097/COH.0b013e328363d3b7. Review.

9.

Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV.

Weaver EA, Nehete PN, Nehete BP, Yang G, Buchl SJ, Hanley PW, Palmer D, Montefiori DC, Ferrari G, Ng P, Sastry KJ, Barry MA.

PLoS One. 2013 Jul 3;8(7):e67574. doi: 10.1371/journal.pone.0067574. Print 2013.

10.

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys.

Teigler JE, Iampietro MJ, Barouch DH.

J Virol. 2012 Sep;86(18):9590-8. doi: 10.1128/JVI.00740-12. Epub 2012 Jul 11.

11.

Selected approaches for increasing HIV DNA vaccine immunogenicity in vivo.

Hutnick NA, Myles DJ, Bian CB, Muthumani K, Weiner DB.

Curr Opin Virol. 2011 Oct;1(4):233-40. doi: 10.1016/j.coviro.2011.08.003. Epub 2011 Sep 7. Review.

12.

Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.

Cottingham MG, Carroll F, Morris SJ, Turner AV, Vaughan AM, Kapulu MC, Colloca S, Siani L, Gilbert SC, Hill AV.

Biotechnol Bioeng. 2012 Mar;109(3):719-28. doi: 10.1002/bit.24342. Epub 2011 Nov 6.

13.

Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge.

Bolton DL, Song K, Wilson RL, Kozlowski PA, Tomaras GD, Keele BF, Lovingood RV, Rao S, Roederer M.

Mucosal Immunol. 2012 Jan;5(1):41-52. doi: 10.1038/mi.2011.45. Epub 2011 Oct 26.

14.

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.

PLoS One. 2011 Apr 13;6(4):e18526. doi: 10.1371/journal.pone.0018526.

15.

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, Marx PA, Gambhira R, Tang H, Montefiori DC, Johnson WE, Rose JK.

J Virol. 2011 Jun;85(12):5764-72. doi: 10.1128/JVI.00342-11. Epub 2011 Apr 13.

16.

Advances and future challenges in adenoviral vector pharmacology and targeting.

Khare R, Chen CY, Weaver EA, Barry MA.

Curr Gene Ther. 2011 Aug;11(4):241-58. Review.

17.

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge.

Geisbert TW, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, Custers J, Vellinga J, Hendriks J, Jahrling P, Roederer M, Goudsmit J, Koup R, Sullivan NJ.

J Virol. 2011 May;85(9):4222-33. doi: 10.1128/JVI.02407-10. Epub 2011 Feb 16.

18.

Protective anti-Pseudomonas aeruginosa humoral and cellular mucosal immunity by AdC7-mediated expression of the P. aeruginosa protein OprF.

Krause A, Whu WZ, Xu Y, Joh J, Crystal RG, Worgall S.

Vaccine. 2011 Mar 3;29(11):2131-9. doi: 10.1016/j.vaccine.2010.12.087. Epub 2011 Jan 6.

19.

Novel adenovirus vector-based vaccines for HIV-1.

Barouch DH.

Curr Opin HIV AIDS. 2010 Sep;5(5):386-90. doi: 10.1097/COH.0b013e32833cfe4c. Review.

20.

Recombinant vector-induced HIV/SIV-specific CD4+ T lymphocyte responses in rhesus monkeys.

Sun Y, Santra S, Buzby AP, Mascola JR, Nabel GJ, Letvin NL.

Virology. 2010 Oct 10;406(1):48-55. doi: 10.1016/j.virol.2010.07.004. Epub 2010 Jul 27.

Supplemental Content

Support Center